Most Cancer Centers Do Not Disclose Payer-Specific Prices

MONDAY, April 18, 2022 (HealthDay News) -- Most U.S. National Cancer Institute-designated cancer centers do not provide required price transparency, but markup on parenteral chemotherapy appears widespread, according to a study published online April 18 in JAMA Internal Medicine.
Roy Xiao, M.D., from Massachusetts Eye and Ear in Boston, and colleagues assessed the extent of price markup by hospitals on parenterally administered cancer therapies and price variation among hospitals. The analysis included private payer-specific negotiated prices for the top 25 parenteral (e.g., injectable or infusible) cancer therapies by Medicare Part B spending in 2019 using publicly available hospital price transparency files.
The researchers found that 27 of 61 National Cancer Institute-designated cancer centers disclosed private payer-specific prices for at least one top-selling cancer therapy as required by federal regulations. Across all centers and payers, median drug price markups ranged from 118.4 percent (sipuleucel-T) to 633.6 percent (leuprolide). Price ratios ranged from 2.2 (pertuzumab) to 15.8 (leuprolide) across centers. Within the same center, negotiated prices also varied considerably between payers, with median within-center price ratios for cancer therapies ranging from 1.8 (brentuximab) to 2.5 (bevacizumab).
"The findings of this cross-sectional study suggest that, to reduce the financial burden of cancer treatment for patients, institution of public policies to discourage or prevent excessive hospital price markups on parenteral chemotherapeutics might be beneficial," the authors write.
Several authors disclosed financial ties to the medical and health insurance industries.
Abstract/Full Text (subscription or payment may be required)
Related Posts
La gripe aviar de un hombre chileno muestra que el virus se adapta a la propagación entre humanos
LUNES, 17 de abril de 2023 (HealthDay News) -- Unas pruebas realizadas a un...
Vinculan los confinamientos por la COVID con una reducción en los nacimientos prematuros
JUEVES, 2 de marzo de 2023 (HealthDay News) -- Los nacimientos prematuros se...
Los efectos de la vacuna contra la COVID se reducen, pero los refuerzos reanudan la protección: estudio
LUNES, 12 de septiembre de 2022 (HealthDay News) -- En todo Estados Unidos se...
Meta-Analysis Shows Decrease in Dementia Risk With HTN Treatment
WEDNESDAY, Nov. 2, 2022 (HealthDay News) -- Antihypertensive treatment is...